BMD: Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones
Study Details
Study Description
Brief Summary
The aims of this study are to collect prospective data on the natural history of bone metastases (BMs) and skeleta related events (SREs),
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The aims of this study are to evaluate clinical and biological factors of patients with BMs after reconstruction with intramedullary fixation (IMN) or endoprosthetic reconstruction (EPR) with a specific focus on (1) the rate of complication or failure; (2) differences in complication rates by anatomic site; (3) functional results as assessed by the Musculoskeletal Tumor Society System (MSTS); (4) differences in complication rate between patients treated with INM versus EPR; and (5) differences in survival in patients with metastatic bone disease based on disease-specific, laboratory, and demographic information.
Study Design
Outcome Measures
Primary Outcome Measures
- Clinical outcomes after treatment of long bone metastases with intramedullary nail versus endoprosthetic reconstruction [24 months]
The study includes the collection of clinical data (age, sex, Karnofsky score) and laboratory data related to the patient (erythrocyte sedimentation rate, C reactive protein, Alkaline phosphatase, white blood cells and hemoglobin) at the time of admission, data on the pathology (histotype, site of bone metastasis , presence of further skeletal or visceral metastases), type of surgery performed (stabilization versus resection).The objectives of this study is to examine clinical outcomes after after surgical treatment of bone metastases with a specific focus on differences in complication rate between patients treated with intramedullary nail versus endoprosthetic reconstruction
Secondary Outcome Measures
- Survival in patients undergoing surgery for metastatic bone disease [24 months]
Provide a reliable and objective means of estimating survival in patients with metastatic bone disease based on disease-specific and laboratory tests
Other Outcome Measures
- Prognostic factor regarding erythrocyte sedimentation rate [24 months]
erythrocyte sedimentation rate (mm/h)
- Prognostic factor regarding C reactive protein [24 months]
C reactive protein (mg/dl)
- Prognostic factor regarding Alkaline phosphatase [24 months]
Alkaline phosphatase (U/L)
- Prognostic factor regarding white blood cells [24 months]
white blood cells (10/mm)
- Prognostic factor regarding hemoglobin [24 months]
hemoglobin (g/dl)
- Prognostic factor regarding Karnofsky score [24 months]
Karnofsky score (0/100)
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with long bone metastases treated surgically with intramedullary nail or endoprosthetic reconstruction
Exclusion Criteria:
- Patients with bone metastases of the spine
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Istituto Ortopedico Rizzoli | Bologna | Italy | 40136 |
Sponsors and Collaborators
- Istituto Ortopedico Rizzoli
Investigators
- Principal Investigator: Costantino Errani, MD, Istituto Ortopedico Rizzoli
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 0012807